CSVTCG-SPECIFIC THROMBOSPONDIN RECEPTOR IN BREAST CANCER

乳腺癌中的 CSVTCG 特异性血小板反应蛋白受体

基本信息

项目摘要

We have recently shown that the CSVTCG (cysteine, serine, valine, threonine, cysteine, glycine) sequence of TSP, a natrix protein that has been implicated in mechanisms of malignancy, functions as a tumor cell adhesion domain and CSVTCG peptides as well as anti-CSVTCG antibodies have anti-metastatic activity in a murine model of lung metastasis. We have also isolated a novel CSVTCG-specific tumor cell adhesion receptor and shown by immunohistochemical staining of human breast tumors that the receptor localizes to malignant ductal epithelium while no staining of epithelium in normal and benign tissues was observed. These studies suggest that the CSVTCG-specific receptor may function to promote the invasive behavior of breast epithelium and contribute to the development of malignancy. To test this hypothesis, we propose to retrospectively correlate the expression of the CSVTCG-specific receptor in human breast tumor samples stored in the MCP tumor bank with patient survival and the presence of metastases in patients at time of diagnosis. In addition, we will determine if patients with borderline cancers such as in situ carcinoma and benign tumors with hyperplasia (which expressed receptor) went on to develop malignant disease. Monoclonal antibodies against the CSVTCG-specific receptor will be prepared in order to further characterize the function and structure of the receptor in tumor cell invasion. The primary structure of human and mouse CSVTCG-receptor will be obtained by cloning their cDNA. The receptor structures as they relate to functions will be determined by a) expression of the receptor, b) construction of chimeric and mutated molecules c) and fragmentation of the receptor. The in vitro and in vivo role of the receptor in breast tumor progression will be assessed by studying the characteristics of receptOr (sense and antisense) in transfected normal and neoplastic breast epithelial cells in tissue culture and in athymic mice. These studies should provide information on the role of the CSVTCG-specific thrombospondin receptor in breast cancer tumor progression and whether the expression of the receptor in breast epithelium can be used diagnostically to predict the invasive phenotype.
我们最近展示了CSVTCG(半胱氨酸,丝氨酸,缬氨酸,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE Paul TUSZYNSKI其他文献

GEORGE Paul TUSZYNSKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE Paul TUSZYNSKI', 18)}}的其他基金

ANGIOCIDIN, A NEW ANGIOGENESIS INHIBITOR
血管抑制素,一种新的血管生成抑制剂
  • 批准号:
    6765993
  • 财政年份:
    2001
  • 资助金额:
    $ 24.66万
  • 项目类别:
Angiociden, A New Angiogenesis Inhibitor
Angiociden,一种新的血管生成抑制剂
  • 批准号:
    6614101
  • 财政年份:
    2001
  • 资助金额:
    $ 24.66万
  • 项目类别:
ANGIOCIDIN, A NEW ANGIOGENESIS INHIBITOR
血管抑制素,一种新的血管生成抑制剂
  • 批准号:
    6514791
  • 财政年份:
    2001
  • 资助金额:
    $ 24.66万
  • 项目类别:
ANGIOCIDIN, A NEW ANGIOGENESIS INHIBITOR
血管抑制素,一种新的血管生成抑制剂
  • 批准号:
    6225727
  • 财政年份:
    2001
  • 资助金额:
    $ 24.66万
  • 项目类别:
ANTIMETASTATIC EFFECT OF THROMBOSPONDIN DERIVED PEPTIDES
血小板反应蛋白衍生肽的抗转移作用
  • 批准号:
    6298828
  • 财政年份:
    2001
  • 资助金额:
    $ 24.66万
  • 项目类别:
ANGIOCIDIN, A NEW ANGIOGENESIS INHIBITOR
血管抑制素,一种新的血管生成抑制剂
  • 批准号:
    6652404
  • 财政年份:
    2001
  • 资助金额:
    $ 24.66万
  • 项目类别:
CSVTCG-SPECIFIC THROMBOSPONDIN RECEPTOR IN BREAST CANCER
乳腺癌中的 CSVTCG 特异性血小板反应蛋白受体
  • 批准号:
    2108756
  • 财政年份:
    1995
  • 资助金额:
    $ 24.66万
  • 项目类别:
THROMBOSPONDIN IN BREAST CANCER INVASION & ANGIOGENESIS
乳腺癌侵袭中的血小板反应蛋白
  • 批准号:
    2113754
  • 财政年份:
    1995
  • 资助金额:
    $ 24.66万
  • 项目类别:
CSVTCG-SPECIFIC THROMBOSPONDIN RECEPTOR IN BREAST CANCER
乳腺癌中的 CSVTCG 特异性血小板反应蛋白受体
  • 批准号:
    6032856
  • 财政年份:
    1995
  • 资助金额:
    $ 24.66万
  • 项目类别:
CSVTCG-SPECIFIC THROMBOSPONDIN RECEPTOR IN BREAST CANCER
乳腺癌中的 CSVTCG 特异性血小板反应蛋白受体
  • 批准号:
    2517610
  • 财政年份:
    1995
  • 资助金额:
    $ 24.66万
  • 项目类别:

相似海外基金

Development of a method for preserving transplanted lung function using Gapmer-type antisense nucleic acid
开发利用Gapmer型反义核酸保存移植肺功能的方法
  • 批准号:
    22K09003
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Myostatin antisense nucleic acid therapy for rhabdomyosarcoma
肌肉生长抑制素反义核酸治疗横纹肌肉瘤
  • 批准号:
    21K07762
  • 财政年份:
    2021
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Suppression of PHOX2B (+7Ala mutant) expression by antisense nucleic acid
反义核酸抑制 PHOX2B(7Ala 突变体)表达
  • 批准号:
    20K16927
  • 财政年份:
    2020
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pathogenesis and Antisense nucleic acid, glycosylation supplementation, and AAV therapy development forFukuyama muscular dystrophy and related diseases
福山性肌营养不良症及相关疾病的发病机制和反义核酸、糖基化补充以及 AAV 疗法的开发
  • 批准号:
    20H00526
  • 财政年份:
    2020
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Synthesis of antisense nucleic acid incorporating cyclic sulfonamide backbone
掺入环状磺酰胺主链的反义核酸的合成
  • 批准号:
    20K21245
  • 财政年份:
    2020
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders
杜氏肌营养不良症及相关疾病的反义核酸剪接校正疗法
  • 批准号:
    G0900887/1
  • 财政年份:
    2011
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Research Grant
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID "2'-PHOSPHORYLATED RNAS" -DIRECTED TOWARD ITS BASIC STRUCTURAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
反义核酸新材料“2-磷酸化RNAS”的化学合成-针对其基础结构研究和HIV病毒表达调控-
  • 批准号:
    05558090
  • 财政年份:
    1993
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research (B)
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID"2"PHOSTHORYLATEDRNAS" DIRETED TOWARD IIS BASIC STRUCTRAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
针对 IIS 基础结构研究和 HIV 病毒表达调控的反义核酸新材料“2”磷酸化 RNA 的化学合成-
  • 批准号:
    04453031
  • 财政年份:
    1992
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了